Glycoconjugate vaccines: an update

M Vella, D Pace - Expert opinion on biological therapy, 2015 - Taylor & Francis
Introduction: Globally, the three main pathogens causing serious infections are
Haemophilus influenzae type b, Streptococcus pneumoniae and Neisseria meningitidis …

[HTML][HTML] The clinical effectiveness of pneumococcal conjugate vaccines: a systematic review and meta-analysis of randomized controlled trials

H Ewald, M Briel, D Vuichard, V Kreutle… - Deutsches Ärzteblatt …, 2016 - ncbi.nlm.nih.gov
Background Streptococcus pneumoniae is responsible for approximately 1.6 million yearly
deaths worldwide. An up-to-date evidence base on the effects of pneumococcal conjugate …

Safety and immunogenicity of the two-dose heterologous Ad26. ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double …

MO Afolabi, D Ishola, D Manno, B Keshinro… - The Lancet Infectious …, 2022 - thelancet.com
Background Children account for a substantial proportion of cases and deaths from Ebola
virus disease. We aimed to assess the safety and immunogenicity of a two-dose …

[图书][B] Bioequivalence and statistics in clinical pharmacology

SD Patterson, B Jones - 2017 - taylorfrancis.com
Maintaining a practical perspective, Bioequivalence and Statistics in Clinical Pharmacology,
Second Edition explores statistics used in day-to-day clinical pharmacology work. The book …

[HTML][HTML] A randomized study of fever prophylaxis and the immunogenicity of routine pediatric vaccinations

J Wysocki, KJ Center, J Brzostek… - Vaccine, 2017 - Elsevier
Objective Prophylactic antipyretic use during pediatric vaccination is common. This study
assessed whether paracetamol or ibuprofen prophylaxis interfere with immune responses to …

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: A …

NK Vadlamudi, K Parhar, KLA Malana, A Kang, F Marra - Vaccine, 2019 - Elsevier
Background Despite the use of 23-valent pneumococcal polysaccharide vaccine (PPV23) in
adults there is substantial morbidity and mortality in the elderly due to pneumococcal …

Mucosal and systemic immunization with a novel attenuated pneumococcal vaccine candidate confer serotype independent protection against Streptococcus …

K Wu, R Yao, H Wang, D Pang, Y Liu, H Xu, S Zhang… - Vaccine, 2014 - Elsevier
Despite the availability of effective vaccines, Streptococcus pneumoniae is still one of the
major infectious diseases causing substantial morbidity and mortality in children under 5 …

Systematic review of published meta-analyses of vaccine safety

RB Dimova, CC Egelebo, HS Izurieta - Statistics in …, 2020 - Taylor & Francis
Meta-analysis can be especially useful for evaluation of vaccine safety, since individual
studies often have limited power to detect an increase in safety risk. To gain a perspective …

[HTML][HTML] La nueva vacuna cubana antineumocócica, de las evidencias científicas disponibles, a la estrategia de evaluación clínica y de impacto

N Linares-Pérez, ME Toledo-Romaní… - Revista Cubana de …, 2017 - scielo.sld.cu
Este trabajo resume el marco de evidencias que sustenta el actual uso de las vacunas
antineumocócicas conjugadas en términos de seguridad, inmunogenicidad, eficacia y …

[HTML][HTML] Il nuovo vaccino coniugato antipneumococcico 15-valente per la prevenzione delle infezioni da S. pneumoniae in età pediatrica: una valutazione di HTA

GE CALABRÒ, F VITALE, C RIZZO… - Journal of Preventive …, 2023 - ncbi.nlm.nih.gov
L'Health Technology Assessment (HTA) è riconosciuto come lo strumento principe per
bilanciare l'esigenza di raggiungere la più ampia accessibilità/copertura possibile al netto …